ClinicalTrials.gg
CompletedNCT03861247Updated Aug 31, 2021

Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients

A Phase 3 interventional study of Phosphate-binder intervention and Phosphorus-restricted dietary intervention in Maintenance Hemodialysis and Hyperphosphatemia, sponsored by Chen Jing. Completed at 2 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-08-31.

Sponsored by Chen Jing · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Hyperphosphatemia with a site in China — 5 open to participants now, 6 under way, 1 of them phase 3. Hyperphosphatemia · China.

Enrollment
9th of 15
123 · median 158
Started
2019
with 2 others
Phase 3
7 of 18
1 open now
Registered
6th of 18
by date
Lead sponsor
1 of 18
Chen Jing

Among the 18 studies in Hyperphosphatemia with a site in China, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 3, and was the 6th registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 15 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

5 of the 18 studies in Hyperphosphatemia with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Hyperphosphatemia studies recruiting now, 10 (83%) set no upper age limit and 2 (17%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hyperphosphatemia with a site in China, or all of them as a file.
02

Study summary

The research is designed as a prospective, randomized, controlled clinical trial without blinding. A total of 116 participants with hyperphosphatemia will be enrolled from three hemodialysis center (56 from Huashan Hospital, 30 from Huadong Hospital and 30 from Tongji Hospital). All participants will be randomly divided into control group and intervention group in a ratio of 1:1. Phosphorus balance status is evaluated in participants of the intervention group by the phosphorus balance calculator. Then, these participants will be given individualized phosphate-binders, dietary and dialysis intervention according to the results of phosphorus balance evaluation. Participants in the control group will not receive the phosphorus balance status evaluation but receive phosphate-binder treatment according to the KDIGO Guidelines. Dietary phosphorus intake, dialysate calcium concentration and dose of active vitamin D, phosphorus-binders of all participants will be recorded during the whole research program. After two-week treatment, the phosphorus balance of participants in intervention group will be evaluated again and the therapeutic strategies then will be adjusted. At the same time, the therapeutic strategies of participants in the control group will be adjusted according to the serum phosphorus concentration. All participants will be followed up for two weeks again and receive blood test and related examinations at the end of study. The results of final examinations will be analyzed to evaluate the efficacy of individualized treatment of hyperphosphatemia.

03

Conditions studied

  • Maintenance Hemodialysis
  • Hyperphosphatemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject within 18-85 years old, male or female.
  2. Subject receiving maintenance hemodialysis 3 times weekly at least 3 months with autologous arteriovenous fistula.
  3. Subject with hyperphosphatemia as defined by serum phosphorus concentration >1.45mmol/L.
  4. Subject in a good general condition with a stable dietary habit.
  5. Subject has insight of the disease and treatment himself/herself and haves ability to communicate with others.
  6. Subject has provided .

Exclusion criteria

Exclusion Criteria:

  1. Subject has residual renal function.
  2. Subject with severe infection, anemia (\<60g/L) or hypoproteinemia (Alb\<30g/L).
  3. Subject has cancer or cachexia.
  4. Subject with a history of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 3 months.
  5. Subject with severe hematopoietic system disease, such as aplastic anemia, thalassemia and thrombocytopenic purpura.
  6. Subject with severe gastrointestinal system disease such as dysphagia, hypohepatia, Active gastrointestinal bleeding, ileus, enterobrosis, or received subtotal gastrectomy.
  7. Subject with disease which affects serum phosphorus concentration such as hypoparathyroidism (iPTH\<11pg/ml), severe hyperparathyroidism (iPTH>600pg/ml) and type 2 vitamin D dependence rickets.
  8. Subject is pregnant.
  9. Subject is currently enrolled in or has completed any other device or drug study\<30 days prior to screening, or is receiving other investigational agents.
  10. Subject has inadequate hemodialysis with a recent spKt/V\<1.2.
  11. Subject has a poor nutritional status with a recent (nPNA\<1.0g/kg/d) .
  12. Subject is not a good participant for the research in the opinion of the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Active comparator
    Control group

    Drug: Phosphate-binder intervention

  • Experimental
    Intervention group

    Drug: Phosphate-binder intervention · Dietary Supplement: Phosphorus-restricted dietary intervention

Interventions

  • DrugPhosphate-binder intervention

    Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .

  • Dietary supplementPhosphorus-restricted dietary intervention

    Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary

    Also known as: Additional dialysis intervention

06

What researchers measure

Primary outcomes

  1. Serum phosphorus concentration

    Time frame: Four weeks after treatment

  2. Achievement rate of serum phosphorus

    Time frame: Four weeks after treatment

Secondary outcomes

  1. Serum calcium concentration

    Time frame: Four weeks after treatment

  2. Serum iPTH concentration

    Time frame: Four weeks after treatment

  3. Serum albumin concentration

    Time frame: Four weeks after treatment

07

Study locations

2 sites
  • Huadong Hospital, Fudan University
    Shanghai, Shanghai 200000, China
  • Tongji Hospital, Tongji University
    Shanghai, Shanghai 200000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jan 2021, 13 months.

Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2019
First posted
Mar 4, 2019
StartActual
Nov 29, 2019
Primary completionActual
Jan 3, 2021
CompletionActual
Apr 15, 2021
Last update
Aug 31, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03861247
Lead sponsor
Chen Jing
Collaborators
Huadong Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine
Responsible party
Chen Jing (Professor, Huashan Hospital) — Sponsor-investigator
First posted
Mar 4, 2019
Start date
Nov 29, 2019
Primary completion
Jan 3, 2021
Completion
Apr 15, 2021
Last update
Aug 31, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion